Fructooligosaccharide associated with celecoxib reduces the number of aberrant crypt foci in the colon of rats.
D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage*; D001397:Azoxymethane / Q000037:antagonists & inhibitors; D002087:Butyrates / Q000378:metabolism; D000068579:Celecoxib; D003106:Colon / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D003110:Colonic Neoplasms / Q000139:chemically induced / Q000517:prevention & control; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004043:Dietary Fiber / Q000008:administration & dosage*; D008297:Male; D009374:Neoplasms, Experimental; D009844:Oligosaccharides / Q000008:administration & dosage* / Q000378:metabolism; D011720:Pyrazoles; D011897:Random Allocation; D051381:Rats; D011916:Rats, Inbred F344; D013449:Sulfonamides / Q000008:administration & dosage*
D016588:Anticarcinogenic Agents; D002087:Butyrates; D016861:Cyclooxygenase Inhibitors; D004043:Dietary Fiber; D009844:Oligosaccharides; D011720:Pyrazoles; D013449:Sulfonamides; C116580:fructooligosaccharide; D000068579:Celecoxib; D001397:Azoxymethane